Ipsen was unable to convince the EMA that Bylvay ... 10,000 patients – given the number of patients targeted under that brand. Its solution was to refile the drug under a different brand name ...

Ipsen and its fellow French partner Genfit are competing with Intercept and Advanz’s Ocaliva, which was approved in 2016 and ...

marking an important step forward in the development of this potential treatment for pediatric low-grade glioma and reinforcing Ipsen’s commitment to innovation in rare and difficult-to-treat ...

After regulatory hold-ups in the US and Europe, Ipsen has claimed a confidence-boosting ... the drug a green light – under the Sohonos brand – to treat fibrodysplasia ossificans progressiva ...

Transaction follows Investment Grade ratings assignment from both S&P and Moody’s PARIS, FRANCE, 19 March 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical ...

PARIS, FRANCE, March 12th, 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care-driven company, announced today the appointment of Olivia Brown as, EVP, Global Head of Neurotoxins ...

Confirmation of full-year 2025 financial guidance. PARIS, FRANCE, 16 April 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents sales for the ...

PARIS, FRANCE, 16 April 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents sales for the first quarter of 2025.

“Ipsen has delivered a strong start to 2025, building further momentum in the transformation of our company,” commented David Loew, Chief Executive Officer, Ipsen. “We continued to execute on our ...

The regulatory filing for tovorafenib was accepted by EMA for review in the European Union, marking an important step forward in the development of this potential treatment for pediatric low-grade ...